CHANGES IN BIOHIT OYJ'S DIAGNOSTICS MANAGEMENT TEAM
BIOHIT OYJ STOCK EXCHANGE RELEASE ON 30 SEPTEMBER 2010 AT 2:00 PM
CHANGES IN BIOHIT OYJ'S DIAGNOSTICS MANAGEMENT TEAM
The Diagnostics Management Team of Biohit Oyj will be reorganized in line with
the new strategy of the Group. The change comes into effect on October 1st 2010.
In addition to the Group's President & CEO, Mr Jussi Heiniö and the General
Director of Diagnostics, Mr Yrjö Wichmann, the new Management Team will include
the following members and functions: Ms Lea Paloheimo (Product Portfolio
Management); Mr Kalle Härkönen (Operations); Ms Terhi Lampén (Sales and
Marketing); Mr Seppo Riikonen (Quality and Risk Management); Ms Tiina Hankonen
(Finance, ICT and HR); and Ms Josefin Hoviniemi (Communications).
The reform reflects the new approach to make the business planning and
operations more efficient and develop the company's business in a truly
international direction, by utilising the Group's own resources and large
network of subsidiaries.
Biohit has two Management Teams. The Diagnostics Management Team focuses on the
diagnostics business and its development, while the Liquid Handling Management
Team focuses on the liquid handling business and its development, as well as
Group-level administration. The Liquid Handling Management Team was reorganized
in beginning of July this year.
Jussi Heiniö
President & CEO
Biohit Oyj
Further information:
Jussi Heiniö
Tel: +358-9-773 861
Email: jussi.heinio@biohit.com
Distribution:
NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com
About Biohit Oyj
Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on
the global market. Biohit's operations are based on a goal-oriented and
long-term innovation and patenting strategy.
Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work as
well as diagnostic tests for the early detection and prevention of diseases of
the gastrointestinal tract.
Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips as
well as pipette maintenance and calibration services for research institutions,
healthcare and industrial laboratories.
The diagnostics business comprises products and analysis systems for the early
diagnosis of gastrointestinal diseases, such as the blood-sample based
GastroPanel examinations for the diagnosis of stomach illnesses and associated
risks, quick tests for the diagnosis of lactose intolerance and H. pylori
infection in connection with gastroscopy, and the ColonView examination for the
early detection of intestinal bleeding that indicates a risk of colorectal
cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic
stomachs.
The Biohit Group employs around 390 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA, as well as a representative office in
Singapore. Additionally, Biohit's products are sold by approximately 450
distributors in 70 countries.
Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small
cap/Healthcare since 1999.
Read more at www.biohit.com
